| INTRODUCTION
Gallbladder cancer is a rare and aggressive disease, with a 5-year survival of 50-13%. [1] [2] [3] Although surgery is the only potentially curative treatment option, long-term survival following surgery is variable, ranging from 10 to 100% at 5 years, and depends on the stage of disease and extent of resection. 1, 4, 5 Approximately 50-70% of gallbladder cancers are found incidentally on pathologic examination after elective cholecystectomy performed for presumed benign disease. [6] [7] [8] [9] Current guidelines for the management of incidental gallbladder cancer (IGBC) state that re-resection should be performed for T1b, T2, and T3 lesions, unless contraindicated by advanced disease or poor performance status. 10 This recommendation is based on the findings that up to 60% of patients have residual disease, much of which is microscopic, in and around the gallbladder fossa at the time of re-resection. [7] [8] [9] 11, 12 Furthermore, re-resection with partial hepatectomy of liver segments IVb/V and portal lymph node dissection is associated with improved survival compared with no reresection. 7, 8, 13 Whether there is a benefit to routine excision of areas outside the gallbladder fossa and portal lymph node basin, such as the peritoneum and abdominal wall fascia surrounding the laparoscopic port sites from the prior cholecystectomy, is questionable.
Some surgeons advocate for routine port-site excision during reoperation for IGBC because, in theory, it may lower the rate of port-site recurrence due to potential contamination from occult tumor seeding during the initial laparoscopic cholecystectomy. 14, 15 Other investigators have questioned this claim, citing a low incidence of disease in port site specimens, increased morbidity, and no difference in survival following the procedure. 16, 17 Due to the rarity of this disease, however, data on IGBC have been largely limited to small cohorts of patients, and in the United States, primarily derive from single-institution analyses. The purpose of this study was to utilize a large, US-based, multi-institutional database to investigate the practice patterns of port site management over time,
as well as to assess the association of port site resection with overall survival (OS).
| METHODS
The Comparative analyses of baseline demographics and clinicopathologic factors between port site and no port site groups are shown in Table 1 . There was no difference in baseline demographics or underlying comorbidities between the two groups. There was also FIGURE 2 Kaplan-Meier curve for overall survival among all patients, comparing port site and no port site resection. Port site resection was not associated with improved survival compared to no port site resection (log rank P = 0.06) FIGURE 3 Kaplan-Meier curve for overall survival among patients with residual disease, comparing port site and no port site resection. Port site resection was not associated with improved survival compared to no port site resection among only patients with residual disease at the time of reoperation (log rank P = 0.44) no difference between groups in the incidence or location of locoregional residual disease at the time of re-resection, the type of resection performed, the incidence of major complications (>Clavien-Dindo grade IIIa), or in pathologic factors, including margin status, T-stage, grade, lymphovascular invasion, perineural invasion, and lymph node status ( Table 1) . Receipt of adjuvant therapy was similar between port site and no port site patients (57% vs. 46%, P = 0.35), as was the incidence of overall disease recurrence (28% vs. 37%, P = 0.38) and, specifically, distant disease recurrence (80% vs. 81%, P = 1.00). 
| DISCUSSION
Incidental gallbladder cancer is a rare malignancy that carries a poor prognosis. Although survival following re-resection of IGBC is improved, it can be highly variable, depending on the stage of disease and extent of resection. 8, 9, 19 Current management guidelines for IGBC recommend a partial hepatectomy of liver segments IVb/V and portal lymphadenectomy, with more extensive resections, such as a major hepatectomy and/or bile duct resection, reserved for cases where necessary to achieve an R0 margin. 10 However, the role of additional resection, such as port site resection, is controversial. In this study, we utilized a large, US-based, multi-institutional database to assess the practice patterns of port site management over time, and investigate the association of port site resection with OS. We found that the rate of port site resection did not change over time, and that port site resection was not associated with improved survival compared with no port site resection.
Citing high rates of disease recurrence at laparoscopic port sites, some surgeons advocate for routine port site resection. 14 Although other more contemporary studies cite a low incidence of port site metastases, even among patients who are at high risk, the utility of port site resection remains debated. 16, 17 In a single-institution review of 69 patients with IGBC who underwent port site resection at Memorial Sloan Kettering Cancer Center, Maker et al 17 reported that 19% had port-site involvement, though only 11% had it among patients with R0 resections. Regardless of margins status, all patients with port site involvement had T2 or T3 disease, and 77% had generalized peritoneal carcinomatosis either at the time of reoperation or shortly thereafter. These data suggest that, rather than mere localized tumor seeding, port site metastases represent a more disseminated problem that may not benefit from operative management. Indeed, when compared to stage-matched patients who did not get port site resections, those who did showed no difference in overall survival, even among only R0 patients. 17 Fuks et al 16 examined 54 patients who underwent port site resection, among whom only one (2%) had port site involvement. This patient developed generalized peritoneal carcinomatosis 7 months after reoperation and died of disease 8 months later. Not only was there no difference in overall survival among patients who underwent port site resection and those patients who did not, the authors reported a 15% incidence of port site incisional hernia associated with port site resection, underscoring the potential morbidity of this procedure. 16 Of the 193 patients included in the current study, 47 (24%) underwent port site resection and 146 (76%) did not. Over the 15-year time period, the rate of port site resections remained constant, ranging from 22% to 33%, despite more recent data suggesting a lack of benefit associated with the procedure. In our cohort, the groups were wellmatched with regards to baseline demographics, operative details, postoperative complications, and pathologic characteristics. In addition, there was no difference between groups in the incidence of finding residual disease at the time of reoperation, the overall recurrence rate, or in the distant disease recurrence rate, the latter representing 80% of the recurrences in both groups. Similar to the studies by Maker et al 17 and Fuks et al 16 , port site resection was not associated with improved OS on univariable or multivariable analysis in our cohort. Although data on specific port site pathology were not available for this study, all patients with disease recurrence at the port sites were categorized as having residual disease at the time of reoperation. Thus, when examining only these patients with residual disease at the time of reoperation, still no association between port site resection and survival was seen. Given that the presence of disease in resected port-site specimens has been additionally associated with distant disease recurrence and generalized peritoneal carcinomatosis, surgical resection of the port sites likely carries very little benefit.
This study has several limitations. First, the retrospective nature of this study makes disease recurrence and survival data difficult to capture, and makes it challenging to draw definitive conclusions from our results. In addition, there may have been a selection bias for who underwent port site resection. However, this study includes data from 10 geographically diverse, academic institutions, which eliminates single-institution bias, and more closely represents the disease characteristics and general practice patterns of the United States.
Furthermore, despite any potential selection bias, groups were wellmatched on all clinicopathologic variables examined. Second, the database utilized for this study lacked information regarding specific port site pathology. Still, our findings mirror those of other more contemporary studies on this topic, and confirm that port site resection is not associated with improved survival, regardless of port site pathology. Finally, pathologic analysis was not standardized across institutions; however, all involved academic centers have experienced GI pathologist who performed all pathologic review.
| CONCLUSION
In conclusion, despite current literature, the practice of routine port site resection during reoperation for incidental gallbladder cancer has not changed over time. Port site resection is not associated with improved overall survival or lower distant disease recurrence. Thus, routine port site resection is not recommended. 
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